Time to be "Overweight" Viking Therapeutics
A World Craving Instant Gratification
We live in a world where almost all Americans own Apple (AAPL) smartphones and where you can instantaneously find almost any information in the world via Alphabet's (GOOGL) Google. Humans (& Americans in particular) often seek quick fixes due to a combination of factors such as impatience, convenience, and a desire for immediate gratification. This tendency is deeply ingrained in human nature and is evident across various aspects of life including health. Quick fixes offer the allure of rapid solutions to complex or challenging problems, promising instant relief or improvement without the need for sustained effort.
Obesity is a Growing Problem
The explosion of processed foods containing unhealthy fats or addictive sweeteners has led to a worldwide obesity epidemic. Obesity levels have increased by 300% over the past 50 years according to the World Health Organization (WHO)! Meanwhile, the World Obesity Atlas predicts that the trend will only worsen, with more than half the world’s population overweight in the next decade.
The Fix
There are two presumable fixes to obesity – eat healthier/exercise, or take an injection drug. Obviously, the second option is controversial. However, many overweight people desperate to lose weight are choosing to go in that direction. According to Goldman Sachs (GS) Research, “Earlier this year, theglobal marketfor anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, it could grow by more than 16 times to $100 billion.”
Biotech powerhouses Eli Lilly (LLY) and Novo Nordisk (NVO) are the first massive winners in the space and have sparked the weight loss treatment revolution. However, on February 27th, Viking Therapeutics (VKTX) shares morethan doubled in a single session after receiving Phase 2 trial for its new injectable weight loss drug. Though LLY and NVO have proven to be big winners and likely will continue to be, I VKTX has much more upside for the following reasons:
VKTX has the Superior Drug
VKTX showed 13% weight loss over a 13-week treatment (with no plateau), while LLY and NVO took much longer (32-48 weeks) to achieve slightly better results (15-20% fat loss). In addition, VKTX saw fewer side effects than its competitors. According to Phase 2 results, VKTX had only a 17% nausea rate (compared to 30-45% for LLY & NVO)
Relatively Small Size/Takeover Target
Novo Nordisk and Eli Lilly each have a market cap north of $500 billion, while Viking has a market cap of just $7 billion. Because the industry has so much upside, VKTX is an obvious takeout target.
Chart + UOA
After exploding on positive results, VKTX is consolidating uniformly and is testing its gap low – an area likely to find buyers.
Image Source: TradingView
Furthermore, VKTX has unusual options activity, with a flurry of buyers of April 90 calls.
Bottom Line
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. VKTX stands to benefit the most.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
Apple Inc. (AAPL) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Alphabet Inc. (GOOGL) : Free Stock Analysis Report
Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report
